



CANN GLOBAL LIMITED
(formerly Queensland Bauxite Limited)
QUARTERLY REPORT
DECEMBER 2018

בס"ד





EXECUTIVE CHAIRPERSON'S REPORT

Pnina Feldman

Dear Shareholders,

It has been a very intense and busy quarter for our company attending to the period of recompliance, release of Prospectus', the Capital Raise (oversubscribed) and internal regulatory compliance. We all are looking forward to relisting and trading as Cann Global Limited ASX:CGB!

We are most pleased to advise that our new company is presently finalising a significant and material partnership agreement regarding our medical cannabis formulations and hemp food consumables which will significantly move forward our production schedule and capacity in 2019, focusing on generating substantial short term revenues for our Company. We will be updating the market with further details on this major development in the coming days.

The CGB Board, management team, and our legal team have been working tirelessly with the ASX and ASIC over the past 6 months to complete this extensive company transformation. We have moved from an Australian Mining Exploration Company with a medical cannabis interest, to expanding the Cannabis division into a Corporate International Medical Cannabis and All-Natural Foods company, with partnerships spanning 4 continents.

Our highly professional management team continues to work with our partner Canntab Therapeutics to have their products and IP exported to Australia. We will provide updates to the market as they become available.

During this period, we have continued to negotiate and sign partnership deals, such as the Pharmocann (Israel) agreement that we believe will provide further lucrative short term revenues for our new Medical Cannabis Divisions.

We are pleased to report that Andrew Kavasilas continues to work with our farmers, and we are very happy with the growth and health of our current hemp crops for the 2019 harvesting season.

The discovery in Israel, by Prof. David (Dedi) Meiri and his team at the Haifa Technion cannabis research lab, has indicated in the lab the potential to significantly control the advancement of the Autoimmune Disease, Multiple Sclerosis. Based on the lab results achieved from the 2018 trials, Prof. Meiri believes that this discovery may prove to have the ability to stop progression of this disease. Mice trials are currently underway, to be followed by voluntary human trials. We are very proud to be associated and provide sponsorship, at the ground floor level, with Dr Meiri and his team. More news to follow on this in 1H 2019.

The Recompliance period has allowed us to attend to any outstanding administrative issues in order to facilitate a smooth transition from ("ASX:QBL" "Queensland Bauxite Limited") to ("ASX:CGB" "Cann Global Limited").


We continue to receive overwhelming support for our Capital Raise, having received over 1100 applications for participation in the share allocation. I am happy to report that we have easily reached our maximum subscription of \$5.95 million dollars and are fully subscribed. We thank our shareholders for giving us the encouragement and support enabling the Company to move forward with all its projects.

The cannabis and nutritional hemp industry in Australia have now completed the first 12 months of legalisation. We have seen a rush of many new players coming onto the Australian market. With our management team, partners with the full suite of licenses, hemp seed farms in 4 states, fully vertically integrated business models, and a large network of wholesale and retail clients in Australia with new customers being signed in China and Vietnam, we firmly believe that in the coming years Cann Global Limited will be one of the major players in this multi-billion dollar burgeoning Cannabis industry.

The Board and management of CGB continues to focus on building very strong foundations, and strengthening business relationships that were formed in 2018. We are very proud of what we have been able to achieve over these past 12 months, as we continue to work hard for the company for the benefit of our investors in building shareholder wealth.

On behalf of the Board and management team of Cann Global, I would like to thank all our shareholders for their continued loyalty and support. I believe as we achieve our milestones, it will become obvious as to why our management team are so excited to be moving ahead into 2019 developing our unique and significant Joint Venture projects.

Yours sincerely,



Pnina Feldman
Executive Chairperson
CANN GLOBAL LIMITED (ASX:CGB)

CANN GLOBAL
LIMITED

Highlights

9th October 2018 Medcan Australia secures ODC
Manufacture License

18th October 2018 MOU signed with a top Israeli
Medicinal Cannabis company,
PharmoCann

24th October 2018 Medcan Australia enters into a
strategic collaboration and
supply agreement with
Canadian LP, Bonify

27th November 2018 CGB, formerly QBL, was
successful in its Federal Court
proceedings for validation
orders

27th November 2018 Annual General Meeting

31st December 2018 End of Quarter



Highlights 2019




On the 14th January, 2019 Queensland Bauxite Limited (ASX:QBL) received formal approval to officially relist its entity onto the ASX under the name Cann Global Limited with the new ticker code (ASX:CGB).

A large, semi-transparent version of the Cann Global Limited logo is overlaid on the right side of the slide, set against a background of a modern glass skyscraper.

CANN GLOBAL
LIMITED



Australian Summer Crops






- New “Summer seedlings” experiencing accelerated growth in favourable climatic conditions across all States

- VitaSeeds team preparing for Feb/March harvest
- Farmers reporting favourable Summer crop health, and size of Hemp plants





VitaHemp...the best nature has to offer



VitaHemp Black Label Products



- Premium Hemp Seed Oil
- Premium Hemp Seed Oil Capsules
 - Hemp Smoothie Blends
 - Hemp Milk



VitaHemp exports



Black Label products

- Premium Hemp Seed Oil
- Premium Hemp Seed Oil Capsules
- Hemp Smoothie Blends
- Hemp Milk




VIETNAM





- Blanck & Co
- Australian Grown Naturals
 - Black Bag
 - EM Foods
 - VitaHemp
 - OMD
- 20 new products





1

DA approved facility

2

ODC Cultivation & Production Licence
ODC Manufacture Licence

3

ODC Import Licence
ODC Export Licence


4

DAWR Permit
(Dept. of Agriculture & Water Resources)
QLD Health Licence - Schedule 9 Substances





- The company will manufacture Pharmocann's range of products under a 50/50 JV for Australian and International distribution
- The company and Pharmocann will collaborate on clinical trials in both Israel and Australia
- Pharmocann will provide IP, standard operating procedures, recipes and manufacturing techniques including existing Israeli clinical trial data in respect of its products
- The company will be responsible for the manufacturing facility, required Australian licences and the raw cannabis material required for product manufacture and international export



The company has signed an MOU with a top Israeli Medicinal Cannabis company, Pharmocann



Appendix 5B

Mining exploration entity and oil and gas exploration entity quarterly report

Introduced 01/07/96 Origin Appendix 8 Amended 01/07/97, 01/07/98, 30/09/01, 01/06/10, 17/12/10, 01/05/13, 01/09/16

Name of entity

Cann Global Limited

ABN

18 124 873 507

Quarter ended ("current quarter")

31 December 2018

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	220	383
1.2 Payments for		
(a) exploration & evaluation	-99	-203
(b) development (MCL)	-641	-1102
(c) production (Vitahemp)	-186	-480
(d) staff costs		
(e) administration and corporate costs	-472	-954
1.3 Dividends received (see note 3)		
1.4 Interest received	32	63
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Research and development refunds		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	-1146	-2293

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment		
(b) tenements (see item 10)		
(c) investments (MCL related Payments)		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
(d) other non-current assets (MCL investments and expenses paid by MCL directly for its business development)		-146
2.2 Proceeds from the disposal of:		
(a) property, plant and equipment		
(b) tenements (see item 10)		
(c) investments		
(d) other non-current assets		
2.3 Cash flows from loans to other entities (Medcan 294K)	-309	-414
2.4 Dividends received (see note 3)		
2.5 Other (GST rebates on MCL expenses)	28	53
2.6 Net cash from / (used in) investing activities	-281	-507

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options		
3.5 Proceeds from borrowings (MCL Directly)	1623	2168
3.6 Repayment of borrowings (MCL Directly)		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
3.10 Net cash from / (used in) financing activities	1623	2168

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	5,592	6,420
4.2 Net cash from / (used in) operating activities (item 1.9 above)	-1146	-2293
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-281	-507
4.4 Net cash from / (used in) financing activities (item 3.10 above)	1623	2168

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.5	Effect of movement in exchange rates on cash held		
4.6	Cash and cash equivalents at end of period	5,788	5,788

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	5,788	5,592
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	5,788	5,592

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	178
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

QBL Directors Fees

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	199
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

Payment for company management and administration services provided under the AGM management services agreement for geological services, secretarial services, bookkeeping, management and administration staff and office rental.

Mining exploration entity and oil and gas exploration entity quarterly report

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Exploration and evaluation	100
9.2 Development	500
9.3 Production	750
9.4 Staff costs	
9.5 Administration and corporate costs	500
9.6 Other (provide details if material)	
9.7 Total estimated cash outflows	1850

10. Changes in tenements (items 2.1(b) and 2.2(b) above)	Tenement reference and location	Nature of interest	Interest at beginning of quarter	Interest at end of quarter
10.1 Interests in mining tenements and petroleum tenements lapsed, relinquished or reduced				
10.2 Interests in mining tenements and petroleum tenements acquired or increased				

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Director/Company secretary)

Date:31st January 2019.....

Print name:Sholom D Feldman.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 6: Exploration for and Evaluation of Mineral Resources and AASB 107: Statement of Cash Flows apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standards apply to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.